ZJSTIC, insurance industry leaders invest over $2M to support Anpac's CDA technology

Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer Dr. Chris Yu announced that Venture Capital (VC) Firm, Shanghai Zhangjiang Science &Technology Investment Corporation (ZJSTIC), as well as private investors related to the insurance industry, have again invested over $2 Million to support Anpac's "Cancer Differentiation Analysis" (CDA) technology.

Impressed by promising results generated from over 25,000 CDA cases to date, the bio-tech-focused VC group and strategic insurance industry leaders invested the equivalency of several million U.S. dollars in 2015, supporting technology listed as, "game changing" and "breakthrough", in Nobel Prize Laureate Summit on Biomedical Science publications.

Anpac's proprietary CDA technology effectively reinvents cancer screening and early detection by analyzing simple, standard, non-invasive "Blood Biopsies" – resulting in measurably greater detection sensitivity and specificity, with no harmful side effects in patients. The results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of diseased cells before tumors form.

Although a young company, Anpac's encouraging CDA findings have led to ongoing collaborations and partnerships with nearly 140 cooperative medical institutions; establishing operations networks that include sample collection, storage, logistics, and sales, in 27 Chinese provinces and four municipalities.

ZJSTIC leaders project Anpac's CDA will be the primary cancer screening method serving much of China's population within five years – and thus an excellent investment opportunity. Partly as a result of ZJSTIC's significant "Series B" investment, Anpac is now establishing a U.S. Headquarters, forming American partnerships, and initiating U.S. FDA clinical trials.

"Anpac has made significant progress validating its innovative, 'game-changing', CDA technology," states Yu. "We continue to demonstrate CDA's multiple advantages over existing technologies; especially in its ease of use and effectiveness detecting early stage cancer through higher sensitivity and specificity, without any side effects. Anpac will use our latest investments to further CDA research and operations in the United States. We are already executing our second round of hiring, establishing partnerships, building multiple labs, and preparing to expedite FDA clinical trials. We are proud our backers continue to reinvest in our company, due to CDA's consistent and ever-increasing effectiveness and success."